Johnson & Johnson (JNJ)
(Delayed Data from NYSE)
$159.69 USD
+0.16 (0.10%)
Updated Oct 8, 2024 04:00 PM ET
After-Market: $159.69 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
C Value D Growth F Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$159.69 USD
+0.16 (0.10%)
Updated Oct 8, 2024 04:00 PM ET
After-Market: $159.69 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
C Value D Growth F Momentum D VGM
Zacks News
Here's Why Merck Stock Is Down in 2017 Despite a Rising Industry
by Zacks Equity Research
Shares of Merck (MRK) have declined so far this year compared to an increase witnessed by the industry due to some notable pipeline setbacks.
Will a 'Huge Tax Cut' Ease Burden for MedTech Players?
by Zacks Equity Research
How is the MedTech industry placed in the wake of the current political conundrum surrounding tax reforms?
JP Morgan Launches US Dividend ETF
by Zacks Equity Research
JP Morgan rolls out multi-cap US Dividend ETF.
J&J Seeks Darzalex's Label Expansion in First-Line Setting
by Zacks Equity Research
Johnson & Johnson (JNJ) has submitted regulatory applications in the United States and EU for label expansion of Darzalex as first-line therapy for multiple myeloma.
J&J & Glaxo Get FDA Approval for First Two-Drug HIV Regimen
by Zacks Equity Research
J&J (JNJ) and Glaxo received FDA approval for Juluca, a two-drug complete regimen of Tivicay/rilpivirine and Edurant/dolutegravir as a single tablet for the treatment of HIV-1 infection.
Quality Dividend ETFs to Tackle Uncertainty
by Zacks Equity Research
Consider these 3 dividend ETFs for your portfolio to fight growing market uncertainty.
United Therapeutics PAH Drug's Exclusivity Period Extended
by Zacks Equity Research
United Therapeutics' PAH drug, Adcirca has been granted six months pediatric exclusivity. This will delay generic competition for the drug for an additional six months.
Glaxo's Triple Therapy COPD Inhaler Gets Marketing Nod in EU
by Zacks Equity Research
Glaxo (GSK) and partner Innoviva announced that their triple combination therapy, Trelegy Ellipta, was granted marketing authorization in the EU as maintenance therapy for the treatment of patients with COPD.
J&J Presents Positive New Data for Diabetes Drug Invokana
by Zacks Equity Research
Johnson & Johnson (JNJ) puts forth positive data from CANVAS study on its type II diabetes drug, Invokana, showing better renal outcomes.
Achillion (ACHN) Shares Down as J&J Announces Stake Sale
by Zacks Equity Research
Achillion's (ACHN) shares fell following the announcement that J&J will sell its complete stake in the company.
Allergan's Vraylar Gets FDA Nod for Maintenance Therapy
by Zacks Equity Research
Allergan's (AGN) schizophrenia capsule, Vraylar, secures an FDA approval for its label expansion as a maintenance treatment option in the market.
Merck (MRK) Gets CHMP Nod for Infection Candidate Prevymis
by Zacks Equity Research
CHMP has given a positive opinion recommending the marketing approval of Merck's (MRK) Prevymis for the prevention of CMV infection.
AstraZeneca Gets Positive CHMP Opinion for Asthma Candidate
by Zacks Equity Research
AstraZeneca (AZN) received CHMP recommendation for marketing approval of its pipeline candidate, benralizumab for treating severe eosinophilic asthma.
Fretting Over Tax Plan Uncertainty? Buy 5 Ultra-Safe Stocks
by Tirthankar Chakraborty
With the markets apprehending a healthy pullback after a strong run, investing in stocks that are immune to market gyrations seems judicious. The best way to go about doing this is by creating a portfolio of ultra-safe stocks.
Impax (IPXL) Q3 Earnings & Revenues Beat Estimates, Fall Y/Y
by Zacks Equity Research
Impax (IPXL) reported dismal third-quarter results with earnings and sales coming in lower than the year-ago period. However, the company beat estimates on both counts.
AstraZeneca (AZN) Misses Q3 Earnings, Tweaks 2017 EPS View
by Zacks Equity Research
AstraZeneca's (AZN) Q3 results were mixed. It expects 2017 core earnings to be toward the favorable end of the guidance range of a decline in low-to-mid teen percentage.
Achillion (ACHN) Q3 Loss Narrows, Pipeline Expansion in Focus
by Zacks Equity Research
Achillion Pharmaceuticals' (ACHN) third-quarter loss was narrower than estimates. The company is focusing on expanding its key pipeline candidate in several indications.
Geron (GERN) Q3 Loss Narrower Than Expected, Sales Miss
by Zacks Equity Research
Geron's (GERN) loss per share in the third quarter was narrower than expected. However, revenues missed estimates. Imetelstat remains in focus.
Pfizer (PFE) Beats on Q3 Earnings, Raises 2017 EPS View
by Zacks Equity Research
Pfizer (PFE) beat expectations for earnings while delivering in-line revenues in Q3. It raised its adjusted earnings guidance while tightening revenue expectations for 2017.
AbbVie (ABBV) Q3 Earnings Top, Revenues In Line, View Up
by Zacks Equity Research
AbbVie's (ABBV) Q3 earnings surpass estimates with revenues matching the same. Sales of the company's lead marketed drug, Humira, also rise year over year.
What's in the Cards for Geron (GERN) this Earnings Season?
by Zacks Equity Research
With no approved product in Geron's (GERN) portfolio, investor focus is likely to remain on its sole pipeline candidate, imetelstat, in the Q3 release.
Zacks Industry Outlook Highlights: Johnson & Johnson, Abbott Labs, Medtronic and Boston Scientific.
by Zacks Equity Research
Zacks Industry Outlook Highlights: Johnson & Johnson, Abbott Labs, Medtronic and Boston Scientific.
Anthem's (ANTM) Q3 Earnings Beat Estimates, Improve Y/Y
by Zacks Equity Research
Anthem's (ANTM) strong third-quarter results were driven by solid enrollment growth.
Is a Beat Likely for Pfizer (PFE) This Earnings Season?
by Zacks Equity Research
While Pfizer's (PFE) new drugs like Ibrance and Xeljanz are likely to drive sales in Q3, genericization of key drugs, pricing pressure and rising competition will hurt sales.
The Zacks Analyst Blog Highlights: Johnson & Johnson, Schlumberger, PayPal, Adobe and Philips
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Johnson & Johnson, Schlumberger, PayPal, Adobe and Philips